Sion­na rais­es $182M for cys­tic fi­bro­sis drugs dif­fer­ent from Ver­tex's ap­proach

Sion­na Ther­a­peu­tics has raised $182 mil­lion in a Se­ries C to test its small mol­e­cules for cys­tic fi­bro­sis by tar­get­ing the mu­tat­ed re­gion of the pro­tein at the root of the dis­ease, un­like Ver­tex Phar­ma­ceu­ti­cals, the drug­mak­er that pi­o­neered med­i­cines for the field.

The over­sub­scribed round was led by Ena­vate Sci­ences, part of the Pa­tient Square Cap­i­tal port­fo­lio, the Boston-based biotech said Wednes­day morn­ing. The in­vestor has al­so backed Sam Wak­sal’s ROCK2 biotech Gravi­ton Bio­science and TYK2 start­up Su­do Bio­sciences in re­cent months.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER